Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association

CHENGDU, Sichuan, China, April 21 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI) was invited by Sino American Biopharmaceutical Association (SABPA) to present at its 5th Annual Biomedical Forum held at Irvine, California on April 24th, 2010. SABPA Biomedical forum focuses on innovations in pharmaceutical and biotechnology industries, as well as business opportunities to thrive in the new economy. The forum provides an attractive platform for entrepreneurs, scientists, investors, executives and policy makers to promote life sciences, biotechnology, pharmaceutical, medical devices and alliances across the biomedical industry.

"We appreciate the invitation by SABPA to interface with a large audience of industrial professionals, entrepreneurs and healthcare investment funds," said Dr. James J. Tong, Chief Financial Officer and Chief Business & Development Officer of Tianyin, "Since 2005, SAPBA conferences have been the forefront to bridge biopharmaceuticals and innovations between the healthcare industry of US and China. We look forward to the in-depth interaction with the biopharmaceutical community in US."

Dr. Jiang, Guoqing, Chairman and CEO of Tianyin Pharmaceutical pointed out, "The past 10 years have seen the rapid expansion of China health care industry, propelled by the economic growth in China, favorable government policies and accelerated demands for pharmaceuticals resulted from an increasing urbanization of a growing population. The ongoing healthcare reform provides further momentum for both generic medicines as well as innovative biopharmaceuticals. Tianyin is positioned to explore the opportunities on both fronts."

SAPBA meeting on 24th of April, McDonald Auditorium, University of California, Irvine from 8:30 am till 4:30 pm (http://www.sabpa.org/web/OCLA/)

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics, equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 50 products, of which 22 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 12 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    Investors Contact:
     James Jiayuan Tong  M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     Tianyin Pharmaceutical Co., Inc.
     Web:   http://www.tianyinpharma.com
     Email: [email protected]
     Tel:   +86-28-8551-6696
            +1-949-350-6999 (U.S.)

    Address:
     23rd Floor Unionsun YangKuo Plaza
     No 2 Block 3 South Renmin Road
     Chengdu, 610041
     China

SOURCE Tianyin Pharmaceutical Co., Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED